"Mannkind is hoping to transform how diabetes is treated with their inhaled insulin product Afrezza. Inhaled insulin is not a new idea, "Exubera" Pfizer's (PFE) try at the market was a major failure for three reasons. First was the delayed onset of action, second was the size of the medication delivery device and third was patients presenting with persistent cough. Mannkind has addressed all three issues with Afrezza in fact the only reason for the CRL by the FDA was the requirement of more data on the medtone inhaler device. The FDA actually had Mannkind enroll children in the current trial, a move usually not taken unless the FDA feels certain of safety and efficacy. Mannkind recently announced completion of their flagship trial and final data is expected in the coming months. www.investors.mannkindcorp.com/phoenix.zhtml . At current valuation I feel Mannkind will offer a more attractive entry point for the late to the party investor. Mannkind has rallied in the past six months from under two dollars a share to roughly seven dollars today. Mannkind currently carries a marketcap in the two billion dollar range. I see approval likely for Afrezza which in turn could easily bring the marketcap of Mannkind to the four billion dollar range. If denied this time around it would most likely spell failure for Mannkind, and its stock price would fall accordingly. Timing of market pullbacks and or bear raids should provide an attractive entry point prior NDA submission in the fall."

http://seekingalpha.com/instablog/984807-chris-lacoursiere/1920321-the-high-stakes-game-of-biotech-investing